Sleep benefit in parkinson's disease
Identifieur interne : 005258 ( Main/Exploration ); précédent : 005257; suivant : 005259Sleep benefit in parkinson's disease
Auteurs : Merello [Argentine] ; Andrew Hughes [Australie] ; Carlo Colosimo [Argentine] ; Marion Hoffman [Australie] ; Sergio Starkstein [Argentine] ; Ramon Leiguarda [Argentine]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-07.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Circadian Rhythm (drug effects), Female, Humans, Levodopa (pharmacology), Male, Middle Aged, Motor Activity (drug effects), Motor fluctuations, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson's disease, Prospective Studies, Questionnaires, Sleep (drug effects), Sleep benefit, Time Factors.
- MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- drug effects : Circadian Rhythm, Motor Activity, Sleep.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged, Prospective Studies, Questionnaires, Time Factors.
Abstract
Sleep benefit (SB) In Parkinson's disease (PD) is not well characterized. To determine SB frequency, as well as to characterize and correlate it with other disease variables, we evaluated prospectively a consecutive series of 312 PD patients by means of a structured questionnaire: 55% reported having SB and 35% reported that awakening was their best time of the day. Because of SB, 21% of the entire population were able to skip or delay medication. The mean duration of the phenomenon was 85.4 ± 67 min. Patients with SB were significantly older (p < 0.0002), had disease longer (p < 0.05), and were often men (X2 = 3.5, df 1, p = 0.05). Patients with SB took sleep medication with similar frequency as those without SB. There were no differences in hours of sleep or sleep latency. Sleep problems such as nightmares or somnambulism, but not the number of sleep awakenings, were similar in both groups. In conclusion, SB is a frequent phenomenon, especially in men, elderly patients, and patients with longer disease duration. SB enables the morning L‐dopa dose to be postponed in ∼50% of patients.
Url:
DOI: 10.1002/mds.870120405
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002D79
- to stream Istex, to step Curation: 002D79
- to stream Istex, to step Checkpoint: 003881
- to stream PubMed, to step Corpus: 004645
- to stream PubMed, to step Curation: 004645
- to stream PubMed, to step Checkpoint: 004573
- to stream Ncbi, to step Merge: 004D38
- to stream Ncbi, to step Curation: 004D38
- to stream Ncbi, to step Checkpoint: 004D38
- to stream Main, to step Merge: 008286
- to stream Main, to step Curation: 005258
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sleep benefit in parkinson's disease</title><author><name sortKey="Merello" sort="Merello" uniqKey="Merello" last="Merello">Merello</name></author><author><name sortKey="Hughes, Andrew" sort="Hughes, Andrew" uniqKey="Hughes A" first="Andrew" last="Hughes">Andrew Hughes</name></author><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name></author><author><name sortKey="Hoffman, Marion" sort="Hoffman, Marion" uniqKey="Hoffman M" first="Marion" last="Hoffman">Marion Hoffman</name></author><author><name sortKey="Starkstein, Sergio" sort="Starkstein, Sergio" uniqKey="Starkstein S" first="Sergio" last="Starkstein">Sergio Starkstein</name></author><author><name sortKey="Leiguarda, Ramon" sort="Leiguarda, Ramon" uniqKey="Leiguarda R" first="Ramon" last="Leiguarda">Ramon Leiguarda</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:24C1A638DBB12162B318227E6E383DEC37A3E879</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120405</idno><idno type="url">https://api.istex.fr/document/24C1A638DBB12162B318227E6E383DEC37A3E879/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002D79</idno><idno type="wicri:Area/Istex/Curation">002D79</idno><idno type="wicri:Area/Istex/Checkpoint">003881</idno><idno type="wicri:doubleKey">0885-3185:1997:Merello:sleep:benefit:in</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9251067</idno><idno type="wicri:Area/PubMed/Corpus">004645</idno><idno type="wicri:Area/PubMed/Curation">004645</idno><idno type="wicri:Area/PubMed/Checkpoint">004573</idno><idno type="wicri:Area/Ncbi/Merge">004D38</idno><idno type="wicri:Area/Ncbi/Curation">004D38</idno><idno type="wicri:Area/Ncbi/Checkpoint">004D38</idno><idno type="wicri:doubleKey">0885-3185:1997:Merello M:sleep:benefit:in</idno><idno type="wicri:Area/Main/Merge">008286</idno><idno type="wicri:Area/Main/Curation">005258</idno><idno type="wicri:Area/Main/Exploration">005258</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sleep benefit in parkinson's disease</title><author><name sortKey="Merello" sort="Merello" uniqKey="Merello" last="Merello">Merello</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Hughes, Andrew" sort="Hughes, Andrew" uniqKey="Hughes A" first="Andrew" last="Hughes">Andrew Hughes</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Neurology Department, Heidelberg Repatriation Hospital, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Hoffman, Marion" sort="Hoffman, Marion" uniqKey="Hoffman M" first="Marion" last="Hoffman">Marion Hoffman</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Neurology Department, Heidelberg Repatriation Hospital, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Starkstein, Sergio" sort="Starkstein, Sergio" uniqKey="Starkstein S" first="Sergio" last="Starkstein">Sergio Starkstein</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Leiguarda, Ramon" sort="Leiguarda, Ramon" uniqKey="Leiguarda R" first="Ramon" last="Leiguarda">Ramon Leiguarda</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Movement Disorders Section, Institute for Neurological Research, Raul Carrea FLENI, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-07">1997-07</date><biblScope unit="vol">12</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="506">506</biblScope><biblScope unit="page" to="508">508</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">24C1A638DBB12162B318227E6E383DEC37A3E879</idno><idno type="DOI">10.1002/mds.870120405</idno><idno type="ArticleID">MDS870120405</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (pharmacology)</term><term>Circadian Rhythm (drug effects)</term><term>Female</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Male</term><term>Middle Aged</term><term>Motor Activity (drug effects)</term><term>Motor fluctuations</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson's disease</term><term>Prospective Studies</term><term>Questionnaires</term><term>Sleep (drug effects)</term><term>Sleep benefit</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Circadian Rhythm</term><term>Motor Activity</term><term>Sleep</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Questionnaires</term><term>Time Factors</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sleep benefit (SB) In Parkinson's disease (PD) is not well characterized. To determine SB frequency, as well as to characterize and correlate it with other disease variables, we evaluated prospectively a consecutive series of 312 PD patients by means of a structured questionnaire: 55% reported having SB and 35% reported that awakening was their best time of the day. Because of SB, 21% of the entire population were able to skip or delay medication. The mean duration of the phenomenon was 85.4 ± 67 min. Patients with SB were significantly older (p < 0.0002), had disease longer (p < 0.05), and were often men (X2 = 3.5, df 1, p = 0.05). Patients with SB took sleep medication with similar frequency as those without SB. There were no differences in hours of sleep or sleep latency. Sleep problems such as nightmares or somnambulism, but not the number of sleep awakenings, were similar in both groups. In conclusion, SB is a frequent phenomenon, especially in men, elderly patients, and patients with longer disease duration. SB enables the morning L‐dopa dose to be postponed in ∼50% of patients.</div></front></TEI><affiliations><list><country><li>Argentine</li><li>Australie</li></country></list><tree><country name="Argentine"><noRegion><name sortKey="Merello" sort="Merello" uniqKey="Merello" last="Merello">Merello</name></noRegion><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name><name sortKey="Leiguarda, Ramon" sort="Leiguarda, Ramon" uniqKey="Leiguarda R" first="Ramon" last="Leiguarda">Ramon Leiguarda</name><name sortKey="Starkstein, Sergio" sort="Starkstein, Sergio" uniqKey="Starkstein S" first="Sergio" last="Starkstein">Sergio Starkstein</name></country><country name="Australie"><noRegion><name sortKey="Hughes, Andrew" sort="Hughes, Andrew" uniqKey="Hughes A" first="Andrew" last="Hughes">Andrew Hughes</name></noRegion><name sortKey="Hoffman, Marion" sort="Hoffman, Marion" uniqKey="Hoffman M" first="Marion" last="Hoffman">Marion Hoffman</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005258 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005258 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:24C1A638DBB12162B318227E6E383DEC37A3E879
|texte= Sleep benefit in parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |